Últimas noticias sobre Quince Therapeutics (NASDAQ:QNCX) Bolsa

Quince Therapeutics

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Quince Therapeutics Inc

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Shopify</strong>.</p>
<p>Looking at options history for Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) we detected 42 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 26% of the investors opened trades with bullish expectations and 52% with bearish.</p>
<p>From the overall spotted trades, 9 are puts, for a total amount of $691,916 and 33, calls, for a total amount of $5,852,437.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $120.0 for Shopify over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Shopify's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Shopify's whale trades within a strike price range from $40.0 to $120.0 in the last 30 days. </p>
<h3>Shopify 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731600949_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$29.4</td>
<td>$28.8</td>
<td>$29.04</td>
<td>$90.00</td>
<td>$1.1M</td>
<td>4.3K</td>
<td>2.0K</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.7</td>
<td>$22.0</td>
<td>$22.7</td>
<td>$115.00</td>
<td>$1.1M</td>
<td>2.2K</td>
<td>1.8K</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$22.6</td>
<td>$22.4</td>
<td>$22.4</td>
<td>$115.00</td>
<td>$672.0K</td>
<td>2.2K</td>
<td>1.8K</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$15.9</td>
<td>$15.15</td>
<td>$15.54</td>
<td>$115.00</td>
<td>$634.6K</td>
<td>6.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$15.55</td>
<td>$15.15</td>
<td>$15.48</td>
<td>$115.00</td>
<td>$485.3K</td>
<td>6.0K</td>
<td>2.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Shopify</h3>
<p>Shopify offers an e-commerce platform primarily to small and medium-size businesses. The firm has two segments. The subscription solutions segment allows Shopify merchants to conduct e-commerce on a variety of platforms, including the company's website, physical stores, pop-up stores, kiosks, social networks (Facebook), and Amazon. The merchant solutions segment offers add-on products for the platform that facilitate e-commerce and include Shopify Payments, Shopify Shipping, and Shopify Capital.</p>
<p>In light of the recent options history for Shopify, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Shopify Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,624,338, the price of SHOP is down by -4.56%, reaching $109.84.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 89 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Shopify</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $112.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Shopify with a target price of $130.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Shopify, targeting a price of $93.<br />
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Shopify with a target price of $94.<br />
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on Shopify with a target price of $125.<br />
&#x2A; Consistent in their evaluation, an analyst from JMP Securities keeps a Market Outperform rating on Shopify with a target price of $120. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Shopify options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

SHOP

Shopify Unusual Options Activity

<p>Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Amgen. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 50% leaning bullish and 25% bearish. Among these notable options, 4 are puts, totaling $137,540, and 4 are calls, amounting to $285,919.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $290.0 to $340.0 for Amgen over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Amgen's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $290.0 to $340.0 in the last 30 days. </p>
<h3>Amgen Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731600944_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$43.6</td>
<td>$43.55</td>
<td>$43.6</td>
<td>$300.00</td>
<td>$196.2K</td>
<td>25</td>
<td align="right">0</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$52.8</td>
<td>$51.5</td>
<td>$51.5</td>
<td>$340.00</td>
<td>$51.5K</td>
<td>190</td>
<td align="right">19</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$10.3</td>
<td>$9.2</td>
<td>$10.0</td>
<td>$310.00</td>
<td>$38.0K</td>
<td>1.8K</td>
<td align="right">62</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$15.65</td>
<td>$15.2</td>
<td>$15.45</td>
<td>$290.00</td>
<td>$33.9K</td>
<td>1.5K</td>
<td align="right">30</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$2.95</td>
<td>$2.08</td>
<td>$2.29</td>
<td>$340.00</td>
<td>$26.5K</td>
<td>112</td>
<td align="right">121</td>
</tr>
</tbody>
</table>
</p>
<h3>About Amgen</h3>
<p>Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.</p>
<h3>Amgen's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 856,173, the AMGN's price is down by -2.03%, now at $295.33. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 82 days.</li>
</ul>
<h3>What Analysts Are Saying About Amgen</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $360.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Bernstein downgraded its action to Outperform with a price target of $380.<br />
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Amgen, targeting a price of $380.<br />
&#x2A; In a cautious move, an analyst from Citigroup downgraded its rating to Neutral, setting a price target of $335.<br />
&#x2A; An analyst from TD Cowen persists with their Buy rating on Amgen, maintaining a target price of $383.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Amgen, targeting a price of $326. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Amgen, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


AMGN

Amgen's Options Frenzy: What You Need to Know

<p>Deep-pocketed investors have adopted a bullish approach towards Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in WMT usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 23 extraordinary options activities for Walmart. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 60% leaning bullish and 26% bearish. Among these notable options, 3 are puts, totaling $153,872, and 20 are calls, amounting to $2,986,061.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $86.67 for Walmart over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Walmart stands at 10636.8, with a total volume reaching 97,378.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Walmart, situated within the strike price corridor from $60.0 to $86.67, throughout the last 30 days.</p>
<h3>Walmart Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731600938_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.57</td>
<td>$2.54</td>
<td>$2.57</td>
<td>$86.67</td>
<td>$476.0K</td>
<td>10.0K</td>
<td>3.6K</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.59</td>
<td>$2.55</td>
<td>$2.58</td>
<td>$86.67</td>
<td>$464.9K</td>
<td>10.0K</td>
<td>6.6K</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.57</td>
<td>$2.55</td>
<td>$2.58</td>
<td>$86.67</td>
<td>$398.6K</td>
<td>10.0K</td>
<td>1.6K</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.58</td>
<td>$2.55</td>
<td>$2.58</td>
<td>$86.67</td>
<td>$231.9K</td>
<td>10.0K</td>
<td>4.6K</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.59</td>
<td>$2.55</td>
<td>$2.58</td>
<td>$86.67</td>
<td>$206.6K</td>
<td>10.0K</td>
<td>7.5K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Walmart</h3>
<p>Walmart serves as the preeminent retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam's Club) and over 10,000 stores globally. Walmart generated over $440 billion in domestic namesake sales in fiscal 2024, with Sam's Club contributing another $86 billion to the company's top line. Internationally, Walmart generated $115 billion in sales. The retailer serves around 240 million customers globally each week.</p>
<h3>Walmart's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,967,114, the price of WMT is up by 0.04%, reaching $85.53.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 5 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Walmart</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $89.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Walmart, targeting a price of $89.<br />
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Walmart with a target price of $87.<br />
&#x2A; Maintaining their stance, an analyst from Telsey Advisory Group continues to hold a Outperform rating for Walmart, targeting a price of $92.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Walmart, which currently sits at a price target of $90.<br />
&#x2A; An analyst from Keybanc persists with their Overweight rating on Walmart, maintaining a target price of $88. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Walmart options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


What the Options Market Tells Us About Walmart

<p>Nvidia&#8217;s CEO, Jensen Huang, shared something surprising during a Fireside Chat at the CASPA 2023 Annual <a href="https://www.youtube.com/watch?v=z8cAXOys3bI">Conference</a>. He said that Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has no long-term plan. This might sound strange coming from the leader of a Big Tech company, but Huang had a simple reason: focus on the present.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Why Jensen Huang doesn't wear a watch: <a href="https://t.co/i1RW625mdI">pic.twitter.com/i1RW625mdI</a></p>
<p>&mdash; Arjun Khemani (@arjunkhemani) <a href="https://twitter.com/arjunkhemani/status/1855613536187142367?ref_src=twsrc%5Etfw">November 10, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"><strong> </strong><strong>for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</strong></a></strong></li>
<li><strong>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai"><strong>Be an early investor with just $1,000 for only $0.50/share today before the offer closes in 2 weeks.</strong></a></strong></li>
</ul>
<p>Huang said that both in his personal life and in leading Nvidia, he doesn't believe in stressing over long-term plans. In fact, he doesn't even wear a watch – on purpose. This choice reflects his belief that the most important time is right now. This mindset, he says, is what <a href="https://www.benzinga.com/markets/equities/24/05/38911606/nvidias-2-trillion-success-story-how-an-act-of-kindness-from-a-top-sega-executive-saved-the-jens">has made Nvidia successful</a>, from graphics cards to artificial intelligence. Instead of worrying about the future, Nvidia works on solving today's problems in the best way possible.</p>
<p>This way of thinking has helped Nvidia become important in gaming, AI, robotics <a href="https://www.benzinga.com/markets/equities/24/09/40939729/energy-meets-ai-schlumberger-teams-up-with-nvidia-to-supercharge-industry-efficiency">and even climate modeling</a>. Huang explained that planning too far ahead can make you miss what's happening right before you. For Nvidia, it means staying flexible and being ready to jump on opportunities as they come – something that has worked well since they've adapted to meet the needs of fields like digital biology and AI.</p>
<p><strong>Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"><strong> </strong><strong>You can still get 4,000 of its pre-IPO shares for just $1,000</strong></a></strong></p>
<p>&#8220;We don't have a long-term strategy,&#8221; Huang <a href="https://x.com/arjunkhemani/status/1855613536187142367">said</a>. &#8220;Our definition of a long-term plan is: what are we doing today?&#8221; By focusing on the present, Nvidia has led in areas like AI and accelerated computing that traditional computing hasn't kept up with.</p>
<p>Not having a strict plan doesn't mean Nvidia has no direction. Instead, it means they are always learning, changing and adjusting based on what's happening right before them. Huang said this approach is why <a href="https://www.benzinga.com/startups/24/09/40692021/nvidia-ceo-jensen-huang-will-push-employees-to-their-limits-but-is-reluctant-to-let-them-go-ill-tort">Nvidia keeps pushing limits</a>, especially with technologies like CUDA, which many doubted initially but <a href="https://www.benzinga.com/news/24/09/40692210/nvidia-maintains-ai-chip-dominance-as-huawei-struggles-to-compete-report">ended up changing computing</a>.</p>
<p><strong>See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"><strong>These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</strong></a></strong></p>
<p>Huang&#8217;s advice for young people or anyone who aspires to achieve was straightforward – concentrate on your current tasks. He thinks every day should be spent doing the finest work possible without worrying too much about the future. This doesn't mean you have no goals; instead, it means letting the present guide you. It's a refreshing way to look at life and work in a world where everyone seems to be rushing toward future goals without focusing on today.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"><strong> </strong><strong>invest today with $1,000 for just $0.25/share</strong></a></strong></li>
<li><strong>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"><strong> </strong><strong>here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before closing date.</strong></a></strong></li>
</ul>


Startups

NVDA

Jensen Huang Reveals 'Nvidia Doesn't Have A Long-Term Strategy' Or Plan. The Reason Behind It Is The Same For Why He Doesn't Wear A Watch

<p>Canaccord Genuity  analyst David Hynes   maintains Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Buy and lowers the price target from $42 to $24.</p>


News

Price Target

Analyst Ratings

ZETA

Canaccord Genuity Maintains Buy on Zeta Global Holdings, Lowers Price Target to $24

<p>Goldman Sachs  analyst Mark Delaney   maintains Innoviz Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) with a Neutral and lowers the price target from $1 to $0.75.</p>


INVZ

Goldman Sachs Maintains Neutral on Innoviz Technologies, Lowers Price Target to $0.75

<p>Canaccord Genuity  analyst Sumant Kulkarni   maintains Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) with a Buy and maintains $14 price target.</p>


VYGR

Canaccord Genuity Maintains Buy on Voyager Therapeutics, Maintains $14 Price Target

<p>Goldman Sachs  analyst Eric Sheridan   maintains Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) with a Sell and lowers the price target from $11 to $8.</p>


GRPN

Goldman Sachs Maintains Sell on Groupon, Lowers Price Target to $8

<p>Canaccord Genuity  analyst Maria Ripps   maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $475 to $525.</p>


SPOT

Canaccord Genuity Maintains Buy on Spotify Technology, Raises Price Target to $525

CPRI

Capri CEO Says Co Is Well Positioned To Move Ahead As An Independent Public Company; Michael Kors Sales Impacted By Slowdown In Luxury Fashion Goods Globally And Outsized Weakness In China; Says Michael Kors Brand Was Not Evolving As Needed

<p>Goldman Sachs  analyst Ben Miller   maintains Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) with a Buy and raises the price target from $8.5 to $11.5.</p>


GENI

Goldman Sachs Maintains Buy on Genius Sports, Raises Price Target to $11.5

<p>Canaccord Genuity  analyst Whitney Ijem   maintains Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) with a Buy and maintains $13 price target.</p>


PASG

Canaccord Genuity Maintains Buy on Passage Bio, Maintains $13 Price Target

<p>Goldman Sachs  analyst Eric Sheridan   maintains Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) with a Neutral and lowers the price target from $3.75 to $1.75.</p>


CHGG

Goldman Sachs Maintains Neutral on Chegg, Lowers Price Target to $1.75

<p>RBC Capital  analyst Pammi Bir   reiterates Plaza Retail REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PLZ#TSX">PLZ</a>) with a Sector Perform and maintains C$4 price target.</p>


Reiteration

TSX:PLZ

TSX:PLZ/UN

RBC Capital Reiterates Sector Perform on Plaza Retail REIT, Maintains C$4 Price Target

<p>Canaccord Genuity  analyst John Newman   maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Buy and maintains $10 price target.</p>


MCRB

Canaccord Genuity Maintains Buy on Seres Therapeutics, Maintains $10 Price Target

<p>Goldman Sachs  analyst Eric Sheridan   downgrades Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) from Buy to Neutral and lowers the price target from $3.25 to $2.5.</p>


Downgrades

ANGI

Goldman Sachs Downgrades Angi to Neutral, Lowers Price Target to $2.5

Trading Ideas

MTEM

Molecular Templates Shares Resume Trade Following Circuit Breaker Halt

<p><strong>ASML Holding NV</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) shared its strategic roadmap during the 2024 Investor Day, highlighting key growth drivers and market expectations through <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41962514/asml-provides-updated-view-on-market-opportunities-at-2024-investor-day-meeting" rel="noreferrer noopener">the decade&#8217;s end</a>.</p>
<p>The semiconductor equipment maker projected significant revenue expansion, with scenarios estimating annual sales of $46.51 billion &#8211; $63.43 billion (44 billion euros &#8211; 60 billion euros) by 2030, alongside a gross margin target of 56%-60%.</p>
<p>CEO Christophe Fouquet sees the company&#8217;s extended lithography portfolio and scalable EUV (Extreme Ultraviolet) technology as crucial assets in capturing the potential of these emerging opportunities.</p>
<p><strong><em>Also Read:</em></strong><em> <a target="_blank" href="https://www.benzinga.com/markets/emerging-markets/24/11/41951575/taiwan-semi-boosts-advanced-chipmaking-with-record-euv-expansion-grabs-56-global-share" rel="noreferrer noopener">Taiwan Semi Boosts Advanced Chipmaking with Record EUV Expansion, Grabs 56% Global Share</a></em></p>
<p>ASML expects robust demand from the semiconductor sector, with projected global sales surpassing $1 trillion by 2030.</p>
<p>This outlook translates to an annual market growth rate of around 9% from 2025 to 2030. The firm anticipates a double-digit CAGR for EUV lithography spending within the same period, focusing on advanced Logic and DRAM nodes.</p>
<p>According to ASML, the integration of AI across industries presents a substantial opportunity for semiconductor firms. The company plans to leverage its EUV capabilities to accommodate the rising need for high-performance chips used in AI applications.</p>
<p>The scalability of EUV technology allows for efficient multi-patterning, which ASML expects will drive greater customer adoption through cost-effective manufacturing processes.</p>
<p>ASML&#8217;s CFO, Roger Dassen, highlighted the company&#8217;s confidence in its financial targets, citing a strong pipeline of product demand and increasing lithography spending.</p>
<p>He restated the company&#8217;s capital allocation strategy, which includes substantial returns to shareholders through dividends and share buybacks.</p>
<p>The company is navigating geopolitical tensions between Washington and China as a U.S. ally.</p>
<p>ASML CEO Christophe Fouquet acknowledges <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41876507/asmls-it-outage-affected-chipmaking-operations-worldwide" rel="noreferrer noopener">rising U.S. pressure</a> to restrict chip technology sales to China. Despite this, China remains ASML&#8217;s top market, primarily for sales of mature chips rather than the advanced AI semiconductors targeted by U.S. export restrictions.</p>
<p>ASML dominates the market for specialized lithography machines, essential for companies like <strong>Taiwan Semiconductor Manufacturing Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) in producing cutting-edge chips used in <strong>Apple Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) smartphones and<strong> Nvidia Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) AI processors.</p>
<p>Reports suggest that Taiwan Semiconductor plans to purchase advanced ASML lithography equipment by the end of the year, with each unit priced at $350 million.</p>
<p><strong>Price Actions:&nbsp;</strong>ASML stock traded higher by 5.09% at $707.67 at the last check on Thursday.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/41977961/mastercards-vision-no-more-passwords-or-card-numbers-by-2030" target="_blank" rel="noreferrer noopener">Mastercard&#8217;s 2030 Vision: A Future Without Passwords, Card Numbers</a></strong></li>
</ul>
<p><em>Photo via ASML</em></p>


Tech

AAPL

ASML

ASML Projects Revenue Surge to $63 Billion by 2030, Eyes AI and Chip Market Boom

<p>Canaccord Genuity  analyst Kyle Mikson   maintains Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Buy and maintains $3 price target.</p>


LUCD

Canaccord Genuity Maintains Buy on Lucid Diagnostics, Maintains $3 Price Target

<p>Canaccord Genuity  analyst Caitlin Cronin   maintains KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) with a Buy and raises the price target from $3 to $4.</p>


KRMD

Canaccord Genuity Maintains Buy on KORU Medical Systems, Raises Price Target to $4

Quince Therapeutics GAAP EPS of -$0.26

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Quince Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/qncx-stock-quote/"><strong>QNCX</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Quince Therapeutics reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/qncx-stock-earnings-quince-therapeutics-for-q1-of-2024/">QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024

Quince Therapeutics GAAP EPS of -$0.64

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Quince Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/qncx-stock-quote/"><strong>QNCX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Quince Therapeutics reported earnings per share of -19 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/qncx-stock-earnings-quince-therapeutics-for-q2-of-2024/">QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

EF Hutton analyst Jason Kolbert initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $12 price target Quince is a biotechnology c...

Quince Therapeutics initiated with a Buy at EF Hutton

Rodman & Renshaw initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $11 price target Published first on TheFly – the ultimate s...

Quince Therapeutics initiated with a Buy at Rodman & Renshaw

Quince Therapeutics (QNCX) announced the poster presentation at the 53rd Child Neurology Society Annual Meeting of safety data from its prior Phase...

Quince Therapeutics presents safety data from ATTeST trial at CNS meeting

Quince Therapeutics (QNCX) "announced the presentation of two posters at the 2024 International Congress for Ataxia Research (ICAR) of data from it...

Quince Therapeutics presents data from prior Phase 3 ATTeST clinical trial

Quince Therapeutics GAAP EPS of -$0.13 beats by $0.02

QNCX

Press Releases

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Comments

Quince Therapeutics

Noticias

Últimas noticias sobre Quince Therapeutics (NASDAQ:QNCX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL